Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 92.

https://doi.org/10.1182/blood.V126.23.92.92

Published: 2015

Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 2862.

https://doi.org/10.1182/blood.V126.23.2862.2862

Published: 2015

Journal Articles

Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

Verena Boehm, PhD, Annett Lebenatus, Marius Bartels, Inga Nagel, PhD, Heiko Trautmann, PhD, Nicola Gökbuget, MD, Dieter Hoelzer, MD, Heike Pfeifer, MD, Reiner Siebert, MD, Michael Kneba, MD, Oliver Ottmann, MD, Monika Brüggemann, MD

Blood (2013) 122 (21): 1327.

https://doi.org/10.1182/blood.V122.21.1327.1327

Published: 2013

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

Blood (2009) 114 (22): 912.

https://doi.org/10.1182/blood.V114.22.912.912

Published: 2009

Journal Articles

Unrelated Allogeneic Stem Cell Transplantation with Myeloablative Conditioning in Adults with Acute Lymphoblastic Leukemia in Remission: Peripheral Blood or Bone Marrow?.

Nadezda Basara, MD, DSc, Myriam Labopin, MD, PhD, Tapani Ruutu, MD, Axel Zander, MD, Oliver Ottmann, MD, Renate Arnold, MD, Vanderson Rocha, MD

Blood (2007) 110 (11): 174.

https://doi.org/10.1182/blood.V110.11.174.174

Published: 2007

Journal Articles

More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.

Heike Pfeifer, MD, Barbara Wassmann, MD, Silvia Wystub, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Hubert Serve, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 10.

https://doi.org/10.1182/blood.V110.11.10.10

Published: 2007

Journal Articles

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Heike Pfeifer, MD, Barbara Wassmann, MD, Sylvia Wystub, MD, Lydia Wunderle, MD, Joerg Chromik, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Anja Binckebanck, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 2817.

https://doi.org/10.1182/blood.V110.11.2817.2817

Published: 2007

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).

Oliver Ottmann, MD, Hagop Kantarjian, MD, Richard Larson, MD, Philipp le Courte, MD, Michele Baccarani, MD, Teresa Rafferty, Aaron Weitzman, MD, Francis Giles, MD

Blood (2006) 108 (11): 1862.

https://doi.org/10.1182/blood.V108.11.1862.1862

Published: 2006

Journal Articles

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Heike Pfeifer, MD, Barbara Wassmann, MD, Anna Pavlova, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Dieter Hoelzer, MD, PhD, Oliver Ottmann, MD

Blood (2006) 108 (11): 639.

https://doi.org/10.1182/blood.V108.11.639.639

Published: 2006

Journal Articles

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

Nicola Goekbuget, MD, Renate Arnold, MD, Johannes Atta, MD, Patrick Brück, MD, Stella Hermann, MD, Heinz Horst, MD, Mustafa Kondakci, MD, Roswitha Kotthoff, Oliver Ottmann, MD, Thorsten Raff, MD, Richard Ratei, MD, Mathias Schmid, MD, Michael Stadler, MD, Dieter Hoelzer, MD, PhD

Blood (2005) 106 (11): 150.

https://doi.org/10.1182/blood.V106.11.150.150

Published: 2005

Journal Articles

The Transcription Factors RUNX1/AML1 and RUNX3/AML2 Protect Bcr-Abl-Transformed B-Cells from Imatinib Induced Apoptosis.

Cornelius Miething, MD, Rebekka Grundler, PhD, Claudia Mugler, Heike Pfeifer, MD, Oliver Ottmann, MD, Simone Barwisch, Michael Speicher, PhD, Christian Peschel, MD, Justus Duyster, MD

Blood (2005) 106 (11): 540.

https://doi.org/10.1182/blood.V106.11.540.540

Published: 2005

Journal Articles

Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML.

Arnold Ganser, MD, Jürgen Krauter, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD, Hans Martin, MD, Michael Lübbert, MD, Jürgen Finke, MD, Wolf Heit, MD, Walter Fiedler, MD, Lothar Kanz, MD, Günter Schlimok, MD, Hartmut Kirchner, MD, Aruna Raghavachar, MD, Peter Brossart, MD, Wolfram Brugger, MD, Gerhard Heil, MD

Blood (2005) 106 (11): 151.

https://doi.org/10.1182/blood.V106.11.151.151

Published: 2005

Journal Articles

Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.

Jürgen Krauter, MD, Gerhard Heil, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD, Hans Martin, MD, Michael Lübbert, MD, Jürgen Finke, MD, Wolf Heit, MD, Walter Fiedler, MD, Lothar Kanz, MD, Peter Brossart, MD, Günter Schlimok, MD, Hartmut Kirchner, MD, Aruna Raghavachar, MD, Wolfram Brugger, MD, Arnold Ganser, MD

Blood (2005) 106 (11): 172.

https://doi.org/10.1182/blood.V106.11.172.172

Published: 2005

Journal Articles

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD, Joachim Beck, MD, Thomas Burmeister, MD, Aristoteles Giagounidis, MD, Axel Glasmacher, MD, Heike Pfeifer, MD, Harald Rieder, MD, Mathias Schmid, MD, Eckhard Thiel, MD, PhD, Barbara Wassmann, MD, Oliver Ottmann, MD, PhD

Blood (2004) 104 (11): 2732.

https://doi.org/10.1182/blood.V104.11.2732.2732

Published: 2004

NARROW

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

Unrelated Allogeneic Stem Cell Transplantation with Myeloablative Conditioning in Adults with Acute Lymphoblastic Leukemia in Remission: Peripheral Blood or Bone Marrow?.

More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

The Transcription Factors RUNX1/AML1 and RUNX3/AML2 Protect Bcr-Abl-Transformed B-Cells from Imatinib Induced Apoptosis.

Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML.

Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only